# ClinicalTrials.gov record NCT04451837

> PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04451837-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04451837-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04451837-semaglutide-v1.json
- Content SHA-256: `99c02d83cb565e735224e2ea2941ef7f50aa293571809ea78030836d0e273e16`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04451837 ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

## Sources

<a id="source-ctg-observation-nct04451837-2025-07-16-10dde460061e"></a>
- **ClinicalTrials.gov record NCT04451837 · retained source version 2025-07-16:10dde460061e9174d0819801109bb8f7a5b879d66182ee005badda8c69b00248** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04451837) (`ctg-observation-nct04451837-2025-07-16-10dde460061e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04451837." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04451837-semaglutide-v1.json SHA-256: 99c02d83cb565e735224e2ea2941ef7f50aa293571809ea78030836d0e273e16.